Search Result
Results for "
NS3 protease
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-I0179
-
|
HCV Protease
|
Infection
|
ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC50: 2131 nM) .
|
-
-
- HY-12946
-
|
Glucocorticoid Receptor
Cytochrome P450
HCV Protease
|
Infection
Inflammation/Immunology
|
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
|
-
-
- HY-144644A
-
-
-
- HY-144644
-
-
-
- HY-163318
-
-
-
- HY-P2502
-
|
HCV Protease
HCV
|
Infection
|
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM .
|
-
-
- HY-16593
-
|
HCV Protease
|
Infection
|
GS-9256 is a selective HCV NS3 protease inhibitor. GS-9256 has good pharmacokinetic properties and antiviral activity .
|
-
-
- HY-P4035
-
|
HCV
|
Infection
|
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .
|
-
-
- HY-144740
-
|
Virus Protease
|
Infection
|
NS2B/NS3-IN-5 (Compound 25b) is an allosteric DENV2 and ZIKV NS2B/NS3 protease inhibitor with IC50 values of 0.67 µM and 4.38 µM against ZIKV and DENV2 NS2B/NS3 proteases, respectively .
|
-
-
- HY-144736
-
|
Virus Protease
|
Infection
|
NS2B/NS3-IN-4 (Compound 34e) is an allosteric DENV2 and ZIKV NS2B/NS3 protease inhibitor with IC50 values of 0.69 µM and 1.04 µM against DENV2 and ZIKV NS2B/NS3 proteases, respectively .
|
-
-
- HY-12946A
-
|
Glucocorticoid Receptor
Cytochrome P450
HCV Protease
|
Infection
Inflammation/Immunology
|
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
|
-
-
- HY-150600
-
|
Virus Protease
Flavivirus
|
Infection
|
NS2B/NS3-IN-7 (compound 26) is a highly potent Zika virus NS2B-NS3 protease inhibitor with a Ki value of 2.33 nM. NS2B/NS3-IN-7 can reduce amounts of ZIKV-infected cells .
|
-
-
- HY-144742
-
|
Virus Protease
|
Infection
|
NS2B/NS3-IN-6 (Compound 1a) is an allosteric DENV and ZIKV NS2B/NS3 protease inhibitor with IC50 values of 2.23 µM and 25.2 µM against ZIKV and DENV proteases, respectively .
|
-
-
- HY-P10657
-
-
-
- HY-10242
-
BILN 2061; BILN 2061ZW
|
HCV
HCV Protease
|
Infection
|
Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with an IC50 of 3.0 nM.
|
-
-
- HY-P10608
-
|
HCV
|
Infection
|
KK4A peptide is a small peptide derived from nonstructural protein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
|
-
-
- HY-10243
-
MK-7009
|
HCV
HCV Protease
|
Infection
|
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
|
-
-
- HY-10235
-
Telaprevir
Maximum Cited Publications
44 Publications Verification
VX-950
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-19840
-
GS-9857
|
HCV Protease
|
Infection
Cancer
|
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .
|
-
-
- HY-P5312
-
|
Virus Protease
|
Infection
|
Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is a WNV NS2B-NS3 protease substrate. Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is used for WNV NS2B-NS3 protease substrate peptide selective inhibitor development .
|
-
-
- HY-N8520
-
|
Bacterial
|
Infection
Cancer
|
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .
|
-
-
- HY-10235S
-
VX-950-d4
|
Isotope-Labeled Compounds
HCV Protease
HCV
SARS-CoV
|
Infection
|
Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-10235R
-
VX-950 (Standard)
|
Reference Standards
HCV Protease
HCV
SARS-CoV
|
Infection
|
Telaprevir (Standard) is the analytical standard of Telaprevir. This product is intended for research and analytical applications. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-P4039
-
|
HCV Protease
|
Infection
|
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .
|
-
-
- HY-126973
-
|
HCV Protease
|
Infection
|
BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity .
|
-
-
- HY-17634
-
ABT-493
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 4.09 μM .
|
-
-
- HY-112254
-
-
-
- HY-10300
-
SCH 900518
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM .
|
-
-
- HY-14434
-
BMS-650032
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-10238
-
ITMN-191; R7227; RO5190591; RG7227
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 0.05 μM .
|
-
-
- HY-W129596
-
|
Virus Protease
Dengue Virus
|
Infection
Inflammation/Immunology
|
Policresulen is a competitive inhibitor for DENV2 NS2B/NS3 protease with an IC50 of 0.48 μg/mL. Policresulen can be used as a local hemostatic and antibacterial agent for research of cervical and vaginal inflammation, skin lesions, oral mucosa and gingival inflammation .
|
-
-
- HY-P4209A
-
|
Virus Protease
|
Others
|
Boc-GRR-AMC (TFA) is a tri-peptide Substrate. Boc-GRR-AMC can be used for a fluorogenic West Nile virus (WNV) substrate, profiling the substrate specificity for the NS2B-NS3 proteases or determining the pH optimum of LdMC activity .
|
-
-
- HY-136797
-
|
Dengue Virus
|
Infection
|
BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
|
-
-
- HY-136575
-
|
Virus Protease
|
Infection
|
4-Hydroxy-2-methylbenzenesulfonic acid ammonium is an impurity of Policresulen. Policresulen is a potent NS2B/NS3 protease inhibitor with an IC50 of 0.48 μg/mL. Policresulen effectively inhibits the replication of DENV2 virus in BHK-21 cells with an IC50 of 4.99 μg/mL. Policresulen acted as a competitive inhibitor of the protease, and slightly affected the protease stability .
|
-
-
- HY-136574
-
|
Virus Protease
|
Infection
|
2-Hydroxy-4-methylbenzenesulphonic acid ammonium is an impurity of Policresulen. Policresulen is a potent NS2B/NS3 protease inhibitor with an IC50 of 0.48 μg/mL. Policresulen effectively inhibits the replication of DENV2 virus in BHK-21 cells with an IC50 of 4.99 μg/mL. Policresulen acted as a competitive inhibitor of the protease, and slightly affected the protease stability .
|
-
-
- HY-136573
-
|
Virus Protease
|
Infection
|
5-Hydroxytoluene-2,4-disulphonic acid diammonium is an impurity of Policresulen. Policresulen is a potent NS2B/NS3 protease inhibitor with an IC50 of 0.48 μg/mL. Policresulen effectively inhibits the replication of DENV2 virus in BHK-21 cells with an IC50 of 4.99 μg/mL. Policresulen acted as a competitive inhibitor of the protease, and slightly affected the protease stability .
|
-
-
- HY-17634R
-
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Glecaprevir (Standard) is the analytical standard of Glecaprevir. This product is intended for research and analytical applications. Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM .
|
-
-
- HY-109571
-
-
-
- HY-10237
-
EBP 520; SCH 503034
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-10300R
-
SCH 900518 (Standard)
|
Reference Standards
HCV
HCV Protease
SARS-CoV
|
Infection
|
Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM .
|
-
-
- HY-14434R
-
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Asunaprevir (Standard) is the analytical standard of Asunaprevir. This product is intended for research and analytical applications. Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-P4038
-
|
HCV Protease
|
Infection
|
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .
|
-
-
- HY-10237S
-
EBP 520-d9; SCH 503034-d9
|
Isotope-Labeled Compounds
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-10237R
-
EBP 520 (Standard); SCH 503034 (Standard)
|
Reference Standards
HCV Protease
HCV
SARS-CoV
|
Infection
|
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-16773
-
GS-9451
|
HCV Protease
BCRP
P-glycoprotein
|
Infection
|
Vedroprevir (GS-9451) is an inhibitor for HCV NS3/4A protease with an IC50 of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC50 of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC50 of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs .
|
-
-
- HY-15256A
-
BI 201335 sodium
|
HCV Protease
|
Infection
|
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .
|
-
-
- HY-P5312A
-
|
Virus Protease
|
Infection
|
Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the acetate salt form of Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr. Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the substrate for WNV NS2B NS3 protease, which is utilized for the development of WNV protease substrate peptide selective inhibitor .
|
-
-
- HY-10241
-
TMC435; TMC435350
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-10241A
-
TMC435 sodium; TMC435350 sodium
|
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-15256
-
BI 201335
|
HCV Protease
|
Infection
|
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .
|
-
- HY-100604
-
|
γ-secretase
Amyloid-β
|
Neurological Disease
|
JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .
|
-
- HY-15298C
-
MK-5172 sodium salt
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15298B
-
MK-5172 hydrate
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir hydrate inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15298
-
MK-5172
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15298A
-
MK-5172 potassium salt
|
HCV
HCV Protease
SARS-CoV
|
Infection
|
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-162485
-
|
Dengue Virus
Virus Protease
|
Infection
|
DV-B-120 is a competitive inhibitor for dengue virus (DENV) with IC50s of 5.35, 7.39, 10.49 and 8.58 μM, for DENV-1, DENV-2, DENV-3 and DENV-4, respectively, by inhibiting NS2B-NS3 protease. DV-B-120 exhibits antiviral activity through inhibition of DENV replication .
|
-
- HY-10241S
-
TMC435-13C,d3; TMC435350-13C,d3
|
Isotope-Labeled Compounds
HCV
HCV Protease
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
- HY-12594
-
ABT-450; Veruprevir
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-131905S
-
|
Isotope-Labeled Compounds
HCV Protease
HCV
|
Infection
Inflammation/Immunology
Cancer
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
- HY-N0110
-
-
- HY-N0110B
-
-
- HY-12594A
-
ABT-450 dihydrate; Veruprevir dihydrate
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-N0110A
-
-
- HY-12594R
-
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-N6841
-
|
Glucose-6-Phosphate Isomerase (GPI)
Casein Kinase
Virus Protease
Flavivirus
PI3K
Akt
mTOR
Apoptosis
|
Infection
Cancer
|
Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral .
|
-
- HY-N0110R
-
-
- HY-114216
-
|
Endogenous Metabolite
|
Infection
|
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-P4039
-
|
Chromogenic Substrates
|
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2502
-
|
HCV Protease
HCV
|
Infection
|
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM .
|
-
- HY-P5510
-
HCV NS3 protease substrate
|
Peptides
|
Others
|
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructural protein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM.
|
-
- HY-P4035
-
|
HCV
|
Infection
|
HCV NS4A Protein (18-40) (JT strain) is an HCV NS4A peptide, which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease .
|
-
- HY-P10657
-
-
- HY-P10608
-
|
HCV
|
Infection
|
KK4A peptide is a small peptide derived from nonstructural protein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
|
-
- HY-P5312
-
|
Virus Protease
|
Infection
|
Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is a WNV NS2B-NS3 protease substrate. Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr is used for WNV NS2B-NS3 protease substrate peptide selective inhibitor development .
|
-
- HY-P4039
-
|
HCV Protease
|
Infection
|
Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease. The sequence EEVVAC is derived from the 5A-5B cleavage junction of the HCV polyprotein .
|
-
- HY-P4209
-
|
Peptides
|
Others
|
Boc-GRR-AMC is a tri-peptide Substrate. Boc-GRR-AMC can be used for a fluorogenic West Nile virus (WNV) substrate, profiling the substrate specificity for the NS2B-NS3 proteases or determining the pH optimum of LdMC activity .
|
-
- HY-P4209A
-
|
Virus Protease
|
Others
|
Boc-GRR-AMC (TFA) is a tri-peptide Substrate. Boc-GRR-AMC can be used for a fluorogenic West Nile virus (WNV) substrate, profiling the substrate specificity for the NS2B-NS3 proteases or determining the pH optimum of LdMC activity .
|
-
- HY-P4038
-
|
HCV Protease
|
Infection
|
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .
|
-
- HY-P5312A
-
|
Virus Protease
|
Infection
|
Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the acetate salt form of Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr. Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate is the substrate for WNV NS2B NS3 protease, which is utilized for the development of WNV protease substrate peptide selective inhibitor .
|
-
- HY-P2435
-
|
Peptides
|
Others
|
Bz-Nle-Lys-Arg-Arg-AMC can be used for protease activity assay. In 0.1mL Tris-HCl buffer (50 mM, pH 7.8), Bz-Nle-Lys-Arg-Arg-AMC was hydrolyzed, and the release rate of AMC was observed .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
Products |
|
Cat. No. |
|
Species |
|
Source |
|
Tag |
|
Accession |
|
Gene ID |
|
Molecular Weight |
|
Purity |
|
Endotoxin Level |
|
Biological Activity |
|
Appearance |
|
Formulation |
|
Storage & Stability |
|
Shipping |
|
Free Sample |
Yes
No
|
Size |
* This product has been "discontinued".
Optimized version of product available:
|
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10235S
-
|
Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-10237S
-
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-10241S
-
|
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
|
-
-
- HY-131905S
-
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: